{
  "id": "64178e34690f196b51000021",
  "type": "yesno",
  "question": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?",
  "ideal_answer": "Yes, viltolarsen is effective for the treatment of Duchenne muscular dystrophy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
    "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
    "http://www.ncbi.nlm.nih.gov/pubmed/36401022"
  ],
  "snippets": [
    {
      "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen restores the reading frame of the DMD gene by skipping \u00a0exon 53\u00a0and produces a truncated but functional form of dystrophin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After showing hopeful results in pre-clinical trials and several clinical trials across North America and Japan, it received US Food and Drug Administration (FDA) approval for DMD\u00a0in 2020.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen restores the reading frame of the DMD gene by skipping \u00a0exon 53\u00a0and produces a truncated but functional form of dystrophin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "esulting in an absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. Herein, long-term (>2 years) functional outcomes in viltolarsen treated pati",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}